Nephro-Urology Monthly

Published by: Kowsar

Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level: A Glimpse into the Future

Mohamed H. Ahmed 1 , *
Author Information
1 Department of Medicine, Milton Keynes Hospital NHS Foundation Trust, Milton Keynes, UK
Article information
  • Nephro-Urology Monthly: November 01, 2013, 5 (5); 1006-1007
  • Published Online: November 13, 2013
  • Article Type: Letter
  • Received: August 13, 2013
  • Accepted: August 26, 2013
  • DOI: 10.5812/numonthly.14179

To Cite: Ahmed M H. Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level: A Glimpse into the Future, Nephro-Urol Mon. 2013 ; 5(5):1006-1007. doi: 10.5812/numonthly.14179.

Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnote
References
  • 1. Hosseini MS, Rostami Z, Einollahi B. Dyslipidemia After Kidney Transplantation and Correlation With Cyclosporine Level. Nephro Urol Mon. 2013; 5(3): 831-4
  • 2. Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant. 2004; 18(3): 274-80[DOI][PubMed]
  • 3. Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr. 2007; 17(1): 97-102[DOI][PubMed]
  • 4. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R, Jr, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004; 4 Suppl 7: 13-53[DOI][PubMed]
  • 5. Ahmed MH, Khalil AA. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transpl. 2010; 21(6): 1021-9[PubMed]
  • 6. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol. 2003; 14(7): 1880-8[PubMed]
  • 7. Kohnle M, Zimmermann U, Lutkes P, Albrecht KH, Philipp T, Heemann U. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transpl Int. 2000; 13 Suppl 1-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments